angiotensin II (Giapreza)
Jump to navigation
Jump to search
Introduction
octapeptide; biologically active component of renin-angiotensin system; formed from angiotensin-I by action of angiotensin converting enzyme.
Function
- stimulates Na+ retention through adrenal formation of aldosterone
- enhances blood vessel contraction
- stimulates thirst through receptors in the brain
Indications
- treatment of hypotension in patients in shock (Giapreza FDA-approved Dec 2017)
Dosage
- 20 ng/kg/min IV by continuous infusion.
- titrate q5min by increments of up to 15 ng/kg/min prn to achieve or maintain target blood pressure
- not to exceed 80 ng/kg/min within 1st 3 hours
- maintenance: do not exceed 40 ng/kg/min
- doses as low as 1.25 ng/kg/min may be used
Monitor
More general terms
Additional terms
References
- ↑ FDA News Release. Dec 21, 2017 FDA approves drug to treat dangerously low blood pressure. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590249.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Khanna A, English SW, Wang XS et al Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. Epub 2017 May 21. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28528561